Capsida

Capsida

Capsida

  • About Capsida
  • Team
  • News & Events
  • Careers
  • Contact
  • About Capsida
  • Team
  • News & Events
  • Careers
  • Contact

News

Capsida Biotherapeutics Debuts with $140 Million of Capital

April 29, 2021

Versant Ventures and Westlake Village BioPartners today announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases.

12

Recent Posts

  • Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
  • Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
  • Capsida Co-Founders Named to Endpoints’ Top 20 Scientists Under 40
  • Capsida Biotherapeutics Announces Appointment of Rayne Waller to Chief Operating Officer
  • PharmaVoice profiles Capsida CEO Peter Anastasiou

© 2022 CAPSIDA - All Rights Reserved.

site by fefifolios